Captrust Financial Advisors Lowers Holdings in Genmab A/S (NASDAQ:GMAB)

Captrust Financial Advisors trimmed its position in Genmab A/S (NASDAQ:GMAB) by 8.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 30,212 shares of the company’s stock after selling 2,611 shares during the quarter. Captrust Financial Advisors’ holdings in Genmab A/S were worth $631,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Genmab A/S in the 4th quarter worth $2,463,000. AIMZ Investment Advisors LLC purchased a new stake in shares of Genmab A/S in the 4th quarter worth $3,525,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Genmab A/S by 229.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock worth $1,033,000 after buying an additional 34,652 shares during the period. Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after buying an additional 1,442 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Genmab A/S by 55.2% in the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock worth $1,205,000 after buying an additional 20,525 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $19.88 on Friday. The business’s 50-day moving average is $19.74 and its 200 day moving average is $20.75. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.06. The firm has a market capitalization of $12.75 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on GMAB. Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. HC Wainwright restated a “buy” rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.